Whitepaper: Risk-Based Quality Management (RBQM)
📄 About This Document
Learn how Risk-Based Quality Management (RBQM) can enhance the quality, efficiency, and oversight of clinical trials. This one-pager outlines the key principles of RBQM, its core components, and insights from a case study on SDV in neurodegenerative studies.
📥 Download the full document to explore how RBQM strategies can optimize your clinical projects.
Related
Peer Reviewed Publication: LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis
LAP-defined Hepatic Steatosis and Cardiometabolic Risk in Rheumatoid Arthritis: A Post-hoc Analysis of the FRANCIS Randomized TrialPatients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease, driven by a complex in...
AAIC 2026 Takeaways: Precision, Biology, and the Evolving Future of Alzheimer’s Trials
The P95 Julius Clinical team recently joined researchers, sponsors, and industry leaders in London for the Alzheimer's Association International Conference (AAIC) 2026. Across plenary presentations, late-breaking sessions, and industry discussions...
Fact Sheet: MASH Clinical Development
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...